Detailed Information on Publication Record
2020
Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
VAN BEEK, Nina, Stine KRÜGE, Tarek FUHRMANN, Susanne LEMCKE, Stephanie GOLETZ et. al.Basic information
Original name
Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
Authors
VAN BEEK, Nina, Stine KRÜGE, Tarek FUHRMANN, Susanne LEMCKE, Stephanie GOLETZ, Christian PROBST, Lars KOMOROWSKI, Giovanni DI ZENZO, Marian DMOCHOWSKI, Kossara DRENOVSKA, Michael HORN, Hana JEDLIČKOVÁ (203 Czech Republic, belonging to the institution), Cezary KOWALEWSKI, Ljiljana MEDENICA, Dedee MURRELL, Aikaterini PATSATSI, Shamir GELLER, Soner UZUN, Snejina VASSILEVA, Xuejun ZHU, Kai FECHNER, Detlef ZILLIKENS, Winfried STÖCKER, Enno SCHMIDT (guarantor) and Kristin RENTZSCH
Edition
Journal of the American Academy of Dermatology, New York, MOSBY-ELSEVIER, 2020, 0190-9622
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30216 Dermatology and venereal diseases
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 11.527
RIV identification code
RIV/00216224:14110/20:00116748
Organization unit
Faculty of Medicine
UT WoS
000582505200038
Keywords in English
autoimmune bullous diseases; biochip; immunofluorescence; pemphigoid; pemphigus
Tags
International impact, Reviewed
Změněno: 13/1/2021 13:57, Mgr. Tereza Miškechová
Abstract
V originále
Background: The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. Methods: Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence-positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lubeck. Results: In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen k for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. Limitations: Laminin 332 and laminin gamma 1 are not represented on the BIOCHIP Mosaic. Conclusions: The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD.